Percutaneous extracorporeal life support in patients with circulatory failure: results of the German Lifebridge Registry

• Published in: The Journal of invasive cardiology Vol. 27; no. 2; pp. 93 - 97
• Main Authors: Jung, Christian, Franz, Marcus, Figulla, Hans-Rainer, Sonntag, Steffen, Hug, Martin, Mudra, Harald, Bauerschmitt, Robert, Kleber, Franz-Xaver, Feindt, Peter, Mehlhorn, Uwe, Vahl, Christian, Bruns, Hans-Juergen, Ferrari, Markus
• Format: Journal Article
• Language: English
• Published: United States 01.02.2015
• Subjects: Extracorporeal Membrane Oxygenation - methods; Female; Germany - epidemiology; Humans; Male; Registries; Retrospective Studies; Shock, Cardiogenic - mortality; Shock, Cardiogenic - therapy; Survival Rate - trends
• ISSN: 1557-2501

Mortality rates remain high in patients with cardiogenic shock or acute refractory circulatory failure. Extracorporeal life support (ECLS) has been recently introduced into clinical practice for treatment of refractory hypotension in selected patients in combination with rapid restoration of gas exchange. The aim of this study was to evaluate the procedural performance and safety of the automated Lifebridge ECLS system (Zoll Lifebridge GmbH). A total of five tertiary cardiovascular centers located in Germany contributed data to this registry (n = 54 patients). Data were collected using a standardized case report form to record clinical characteristics, demographic, procedural, and follow-up data. Patients were included if they were in circulatory crisis (caused by cardiogenic shock or ongoing resuscitation) in an acute setting or in an elective setting during high-risk percutaneous intervention. The Lifebridge device was successfully used in all patients. During elective use, no complications occurred besides 1 minor vascular injury. All elective patients were successfully weaned from the device and alive at the primary endpoint after 30 days. In the emergency setting, 85% of the patients were successfully weaned from the device and 49% of the patients were alive after 30 days. Relevant bleeding resulting in transfusion of red blood cells occurred in 5% of patients. In this observational study, we report data from the real-world use of a novel automated ECLS system. Elective use of Lifebridge was feasible and safe without major side effects. In the emergency setting, mortality rates were high; however, stabilization of the selected patients was safe and feasible.